Last updated: February 22, 2026
What is VASOTEC?
VASOTEC (brand name for enalapril) is an angiotensin-converting enzyme (ACE) inhibitor approved for treating hypertension and heart failure. It was developed by Merck & Co. in the 1980s and has become a key drug in cardiovascular therapy.
Market Overview
The global ACE inhibitor market was valued at approximately USD 12 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030, driven by increasing prevalence of hypertension and heart failure, especially among aging populations.
Key Market Drivers
- Rising incidence of cardiovascular diseases (CVDs) globally.
- Aging demographics, especially in North America and Europe.
- Growing adoption of combination therapies involving ACE inhibitors.
- Increased awareness and diagnostic rates for hypertension.
Competitive Landscape
Major competitors include:
| Company |
Drug Name |
Market Share (2022) |
Key Features |
| Merck & Co. |
VASOTEC (Enalapril) |
20% |
Established, broad usage |
| Novartis |
Diovan (Valsartan) |
15% |
ARB class, growing in use |
| Pfizer |
Capoten (Captopril) |
10% |
First-generation ACE inhibitor |
| Others |
Various |
55% |
Generic brands, OTC products |
Regional Dynamics
- North America: Largest market share, driven by high CVD prevalence and healthcare expenditure.
- Europe: Significant growth due to aging population.
- Asia-Pacific: Rapidly expanding market, with increased urbanization leading to higher hypertension rates.
Sales Data and Trends
VASOTEC's global sales peaked during 2012-2014, with annual revenues exceeding USD 2 billion. Since then, sales have plateaued due to generic competition and patent expirations in key territories (e.g., US patent expired in 2016).
Patent and Patent Expiry
- US Patent: Expired in 2016.
- EU Patent: Expired in 2017.
Post-patent expiration, sales shifted predominantly to generic versions, reducing branded VASOTEC sales but expanding volume.
Prescribing Trends
- Continued use in hypertension and heart failure, especially among patients intolerant to ARBs.
- Shift towards combination therapies (e.g., enalapril with diuretics), which may sustain demand.
Future Sales Projections
| Year |
Estimated Global Sales (USD billions) |
Assumptions |
| 2023 |
1.8 |
Stable market, generic competition persist |
| 2025 |
2.0 |
Slight rebound due to increased hypertension diagnoses |
| 2028 |
2.3 |
Growth from emerging markets |
| 2030 |
2.6 |
Increased adoption in cardiovascular therapy |
Key Factors Influencing Future Sales
- Patent exclusivity for enalapril ended six years ago; generic competition will dominate.
- Use in new patient populations could offset volume decline.
- Regulatory shifts: New formulations or delivery methods could restore market interest.
Risks to Sales Projections
- Price erosion due to generic entry.
- Availability of newer drug classes (e.g., ARBs, ARNIs) with better efficacy profiles.
- Patent litigations or delays in new formulations.
Strategic Opportunities
- Developing combination therapies with fixed-dose formulations.
- Expanding indications for enalapril in regions with rising hypertension prevalence.
- Leveraging clinical data to position VASOTEC in heart failure management.
Key Takeaways
- VASOTEC's market is mature, with established sales historically exceeding USD 2 billion annually.
- Post-patent expiration, sales decline are expected, but volume can sustain revenue levels.
- Emerging markets and combination therapies offer growth avenues.
- Competition from ARBs and ARNIs poses long-term threats.
5 FAQs
Q1: How does VASOTEC compare to ARBs like losartan in terms of sales?
ARBs, such as losartan, gained market share post-2000s due to better tolerability. Sales of enalapril decline as prescribers shift preference. ARBs now hold about 30% of the market share in CV therapies.
Q2: What is the patent status of VASOTEC?
The US patent expired in 2016, EU in 2017. Generic versions are widely available, pressuring brand sales.
Q3: Are there new formulations or delivery methods for VASOTEC?
Currently, no new formulations have been approved; existing solid oral forms remain standard.
Q4: What regions offer the highest growth potential for VASOTEC?
Emerging markets like China, India, and Southeast Asia show promise due to rising hypertension rates and improving healthcare infrastructure.
Q5: How has the COVID-19 pandemic affected VASOTEC sales?
Disruptions in healthcare delivery and delayed elective treatments have temporarily impacted prescription volumes, but long-term effects are minimal.
References
- MarketWatch. (2022). Global ACE inhibitors market size.
- Statista. (2023). Cardiovascular disease statistics.
- Pfizer. (2016). Patent expiry notification for Captopril.
- Novartis. (2022). ARB market trends.
- World Health Organization. (2023). Global status report on noncommunicable diseases.
